Dr Barry Buckland Joins the Mucosis B.V. Supervisory Board

Dr Barry Buckland Joins the Mucosis B.V. Supervisory Board
Groningen, the Netherlands, 12 November 2010 -- Dutch biotechnology company Mucosis B.V. announced today that Dr Barry Buckland was elected to its Supervisory Board. Dr Buckland brings extensive experience in vaccine design and development.

From 1996 to 2009, Dr Buckland was Vice President, BioProcess R&D at Merck & Co, Inc. He built the unit and was responsible for process development for 14 new commercial products, including 10 new vaccines. More recently Dr Buckland has been a consultant to Hilleman Laboratories, the vaccine venture established between Merck and The Wellcome Trust. Dr Buckland received many professional and academic honors, including the 2008 Marvin Johnson Award from the American Chemical Society for lifetime contribution to biotechnology. He has authored 77 scientific papers.

"I am delighted to have this opportunity to contribute to the success of Mucosis" commented Dr Buckland. "The Company's mucosal immunity platform will have many applications in developing superior vaccines".

John Lambert, Chairman of Mucosis added: "Barry's insight and experience stem from being involved in the design, development and commercialization of many of today's blockbuster vaccines. He will be invaluable to Mucosis".

 

For further information please contact:

Govert Schouten CEO Mucosis +31 (6) 55320948 [email protected] www.mucosis.com

 

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.